<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107871</url>
  </required_header>
  <id_info>
    <org_study_id>90760</org_study_id>
    <secondary_id>1U01DC014706-01A1</secondary_id>
    <nct_id>NCT03107871</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants</brief_title>
  <acronym>ValEAR</acronym>
  <official_title>Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to determine the clinical benefit and safety of antiviral&#xD;
      therapy for asymptomatic congenital cytomegalovirus (cCMV) infected hearing-impaired infants.&#xD;
      We will conduct a multi-center double-blind randomized placebo-controlled trial to determine&#xD;
      whether hearing-impaired infants with asymptomatic cCMV have better hearing and language&#xD;
      outcomes if they receive valganciclovir antiviral treatment. We will also determine the&#xD;
      safety of antiviral valganciclovir therapy for asymptomatic cCMV-infected hearing impaired&#xD;
      infants. This study will be unique in that the cohort enrolled will only include&#xD;
      hearing-impaired infants with asymptomatic cCMV.&#xD;
&#xD;
      Primary Objective: To determine if treatment of cCMV-infected hearing impaired infants with&#xD;
      isolated hearing loss with the antiviral drug valganciclovir reduces the mean slope of total&#xD;
      hearing thresholds over the 20 months after randomization compared to untreated cCMV-infected&#xD;
      infants with isolated hearing loss.&#xD;
&#xD;
      Main Secondary Objectives:&#xD;
&#xD;
        1. To determine if valganciclovir treatment improves the following outcomes when compared&#xD;
           to the control group:&#xD;
&#xD;
             1. The slope of best ear hearing thresholds over the 20 months after randomization.&#xD;
&#xD;
             2. The MacArthur-Bates Communicative Development Inventory (CDI) percentile score for&#xD;
                words produced at 20 months of age.&#xD;
&#xD;
        2. To evaluate safety measures based on all grade 3 or greater new adverse events&#xD;
           designated by the NIAID Division of AIDS (DAIDS) toxicity tables.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cytomegalovirus (CMV) can be transmitted from the mother to the fetus and is a leading cause&#xD;
      of sensorineural hearing loss (SNHL), which is a condition where the inner ear is unable to&#xD;
      convert sound into nerve impulses to the brain. This hearing loss and its detrimental effect&#xD;
      on language development contribute nearly $4 billion annually to the health care costs in the&#xD;
      U.S. Unlike other types of SNHL, CMV induced hearing loss can be treated. Several clinical&#xD;
      trials have demonstrated that antiviral therapy may prevent progressive hearing loss if&#xD;
      administered early in life for severely affected (symptomatic CMV) infants. These promising&#xD;
      findings have given rise to a debate regarding the best method for identifying and treating&#xD;
      the more numerous asymptomatic CMV-infected infants.&#xD;
&#xD;
      One approach is to conduct universal newborn hearing screens, and then do CMV diagnostic&#xD;
      testing only on the infants who fail the hearing screen. This targeted approach should&#xD;
      identify those infants at greatest risk of developing progressive hearing loss and consequent&#xD;
      communicative difficulties. Utah is the first state to mandate this approach whereby infants&#xD;
      under three weeks of age who fail their newborn hearing screening undergo CMV testing. In&#xD;
      this trial, the hearing screen targeted approach will be used to identify patients eligible&#xD;
      for participation in a double blind placebo controlled randomized clinical trial of antiviral&#xD;
      valganciclovir therapy. The results of this trial will inform public policy, potentially&#xD;
      shift our current clinical practice regarding pediatric hearing loss evaluation, and&#xD;
      potentially offer a therapeutic option to asymptomatic CMV-infected infants with SNHL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2018</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo and active drug will be dispensed in identical amber bottles with identical labeling.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total Ear Hearing Slope</measure>
    <time_frame>Assessed at baseline, 8, 14 and 20 months post-randomization</time_frame>
    <description>The primary objective of this randomized trial is to determine if treatment of cCMV-infected infants with isolated hearing loss with the antiviral drug valganciclovir reduces the slope of the total ear hearing thresholds over the 20 months after randomization compared to that of untreated cCMV-infected infants with isolated hearing loss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Ear Hearing Slope</measure>
    <time_frame>Assessed at baseline, 8, 14 and 20 months post-randomization</time_frame>
    <description>The computation of the slope of the best-ear hearing thresholds begins with the same preliminary averaging steps across MRLs and truncation of threshold levels to between 15 and 110 dB as is described above for the total ear hearing slope, but in this case the analysis is based on the best-ear hearing score at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentile Score for Words Produced Endpoint</measure>
    <time_frame>Assessed at 20 months of age</time_frame>
    <description>The main communicative development endpoint will be determined based on the MacArthur-Bates CDI words produced percentile score given at 20 months of age.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Words Produced Below 10th Percentile</measure>
    <time_frame>14 and 20 month of age assessments</time_frame>
    <description>Dichotomous endpoint defined by children's communicative competency as above or below the 10th percentile based upon on the number of words produced.</description>
  </other_outcome>
  <other_outcome>
    <measure>Additional MacArthur Bates - Words and Sentences Subscale Percentiles</measure>
    <time_frame>20 month of age assessment</time_frame>
    <description>The percentile scores for the MacArthur Bates Communicative Development Inventory Words and Sentences for complexity and the word form subscales, and the mean length utterance.</description>
  </other_outcome>
  <other_outcome>
    <measure>MacArthur Bates - Words and Gestures Subscale Percentiles</measure>
    <time_frame>14 months of age assessment</time_frame>
    <description>Secondary communicative development endpoints will be obtained from parent report on the MacArthur Bates Communicative Development Inventory - Words and Gestures form at 14-months. The scores will be the percentile scores for the total number of words produced, total gestures, phrases understood and words understood.</description>
  </other_outcome>
  <other_outcome>
    <measure>Developmental Domain Endpoints</measure>
    <time_frame>14 and 20 months of age assessments</time_frame>
    <description>Based on parent report on the Ages and Stages Questionnaire, 3rd Edition. There are five subtests on the ASQ-3. These include communication, gross motor, fine motor, problem solving, and personal- social. We will use the following scores:1)Raw scores from each subtest 2)Dichotomous endpoints for each subtest based upon the raw score above or below a designated cut-off score based upon age</description>
  </other_outcome>
  <other_outcome>
    <measure>Valganciclovir Pharmacokinetics</measure>
    <time_frame>From week 2 to month 6 post-randomization</time_frame>
    <description>Valganciclovir drug levels will be measured.</description>
  </other_outcome>
  <other_outcome>
    <measure>Viral Resistance</measure>
    <time_frame>Assessed at month 7 post-randomization</time_frame>
    <description>The presence of viral resistance will be measured.</description>
  </other_outcome>
  <other_outcome>
    <measure>Viral Load</measure>
    <time_frame>Assessed at baseline month 3, and month 7 post-randomization</time_frame>
    <description>Viral load will be measured</description>
  </other_outcome>
  <other_outcome>
    <measure>LittlEARS</measure>
    <time_frame>14 and 20 months of age assessments</time_frame>
    <description>The raw scores will be dichotomized based on the child's hearing age and compared to standardized scores.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Cmv Congenital</condition>
  <condition>CMV</condition>
  <condition>Congenital Cmv</condition>
  <condition>SNHL</condition>
  <condition>Sensorineural Hearing Loss</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valganciclovir 16 mg/kg PO twice daily (BID) x 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Flavored Simple Syrup, volume equivalent to active arm dose, PO BID x 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Valcyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simple Syrup</intervention_name>
    <description>Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Sucrose Water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 1 month and less than or equal to 12 months at the time&#xD;
             of randomization; AND&#xD;
&#xD;
          -  Positive congenital CMV by urine culture or polymerase chain reaction test(PCR), OR&#xD;
             saliva culture or PCR followed by confirmatory urine PCR by 21 days of age, OR urine&#xD;
             culture or PCR after 21 days of age followed by newborn dry blood spot PCR; AND&#xD;
&#xD;
          -  Confirmed sensorineural hearing loss (SNHL) by auditory brainstem response (ABR)&#xD;
             testing. For ABR assessments, hearing loss is defined as levels greater than 25 dB&#xD;
             normal hearing levels (NHL) at 1, 2, or 4 kHz in one or both ears.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Imminent demise; OR&#xD;
&#xD;
          -  Known hypersensitivity reaction to valganciclovir, ganciclovir, or any components of&#xD;
             the investigational product formulation; OR&#xD;
&#xD;
          -  ALT (Alanine Aminotransferase) five times baseline U/L, hepatomegaly, or significant&#xD;
             gastrointestinal disorders (e.g., eosinophilic esophagitis, ulcerative colitis); OR&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) less than 500 cells/mm^3, Hemoglobin less than 8 g/dL,&#xD;
             or platelets less than 50,000/mm^3, splenomegaly, or significant hematologic disorders&#xD;
             (e.g., hemophilia, leukemia, sickle cell anemia); OR&#xD;
&#xD;
          -  Creatinine clearance less than 60 mL/min/1.73m^2 or significant renal disorders (e.g.,&#xD;
             nephrotic syndrome); OR&#xD;
&#xD;
          -  Receiving other antiviral medications or immune globulin therapy; OR&#xD;
&#xD;
          -  Receiving other investigational drugs; OR&#xD;
&#xD;
          -  Breast feeding from a mother receiving antiviral or immunosuppressive medication; OR&#xD;
&#xD;
          -  Known HIV positive mother (risk of immunosuppression); OR&#xD;
&#xD;
          -  Subject is currently using list of prohibited medication specified by the package&#xD;
             insert; OR&#xD;
&#xD;
          -  Other known cause contributing to SNHL (e.g., meningitis, aminoglycoside ototoxicity);&#xD;
             OR&#xD;
&#xD;
          -  Bilateral profound SNHL or auditory neuropathy spectrum disorder; OR&#xD;
&#xD;
          -  Existing conductive hearing loss or mixed permanent hearing loss is present; OR&#xD;
&#xD;
          -  Evidence of intracranial calcification; OR&#xD;
&#xD;
          -  Evidence of hydrocephalus; OR&#xD;
&#xD;
          -  Microcephaly; OR&#xD;
&#xD;
          -  Presence of petechiae; OR&#xD;
&#xD;
          -  Intrauterine growth retardation; OR&#xD;
&#xD;
          -  Chorioretinitis, optic atrophy or pale optic nerves; OR&#xD;
&#xD;
          -  Parent or guardian unable to speak English or Spanish; OR&#xD;
&#xD;
          -  Subject exposed to a language other than English or Spanish a majority of the time; OR&#xD;
&#xD;
          -  Subject unable to complete hearing assessments or parent/guardian unable to complete&#xD;
             communication questionnaires; OR&#xD;
&#xD;
          -  &lt; 32 weeks gestational age at birth; OR&#xD;
&#xD;
          -  Weight at the time of birth &lt; 1800 g.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashlea Wilkes, CCRC</last_name>
    <phone>801-587-8145</phone>
    <email>ashlea.wilkes@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Austin Stevens, BSN</last_name>
    <phone>801-213-6985</phone>
    <email>austin.stevens@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Cheng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Carvalho, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dylan Chan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Goudy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leena Mithal Bhattacharya, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Doscolo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Smith, MD</last_name>
      <phone>888-573-5437</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Cohen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan H Pesch, MD</last_name>
      <phone>734-936-9777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Masonic Children's Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Schleiss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Neff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis Universtiy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Brinkmeier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Dartmouth-Hitchcock</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Saunders</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Hawley, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Nassar, MD</last_name>
      <phone>718-696-4016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan A Kohlhoff, MD</last_name>
      <phone>718-270-2271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine M Salvatore, MD</last_name>
      <phone>646-962-6845</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Grunstein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Sood, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Sanchez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol MacArthur, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Germiller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monroe Carell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Virgin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth H Lee, MD</last_name>
      <phone>844-424-4537</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Harrison, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Park, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Antonio, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Melvin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic Research Institute</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Pernica, MD</last_name>
      <phone>9055259140</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of London Health Science Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Barton-Forbes, MD</last_name>
      <phone>5196858500</phone>
      <phone_ext>58299</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Brophy, MD</last_name>
      <phone>6137377600</phone>
      <phone_ext>2651</phone_ext>
      <email>JBrophy@cheo.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sean A Bitnun, MD</last_name>
      <phone>4168137654</phone>
      <phone_ext>3362</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Albert Park</investigator_full_name>
    <investigator_title>Chief Peds Otolaryngology</investigator_title>
  </responsible_party>
  <keyword>valganciclovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

